Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Medicenna Therapeutics Corp
T.MDNA
Alternate Symbol(s):
MDNAF
Healthcare
Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL...
-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:MDNA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Next
(120)
•••
ENEMENEMYNEMO
X
View Profile
View Bullboard History
Comment by
ENEMENEMYNEMO
on Apr 09, 2024 7:59pm
RE:RE:RE:RE:Abstract
Good luck to ya!
(580)
•••
Galaxym31
X
View Profile
View Bullboard History
Comment by
Galaxym31
on Apr 09, 2024 7:42pm
RE:RE:RE:Abstract
4 PR , 3 SD not feeling it I think they had about 160 people in the GBM trial , if the SP moves up I will unload .
(120)
•••
ENEMENEMYNEMO
X
View Profile
View Bullboard History
Comment by
ENEMENEMYNEMO
on Apr 09, 2024 5:54pm
RE:RE:Abstract
Does a Clinical Benefit Rate of 50% make you a happier investor Galaxie?
(217)
•••
13X2413
X
View Profile
View Bullboard History
Comment by
13X2413
on Apr 09, 2024 4:46pm
RE:RE:RE:Update tomorrow better be good eh .
Hope not. Today's knocked it down 20 cents. Was the news kind of disappointing?
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 09, 2024 4:30pm
New Press Release - Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to date which include 2 of 4 evaluable dose expansion patients and 2 of 2 MSI-H patientsDurable stable disease (SD) in 3 melanoma patients for 6 to 18 months with concomitant...
read article.
(99)
•••
windymayor1
X
View Profile
View Bullboard History
Comment by
windymayor1
on Apr 09, 2024 4:05pm
RE:RE:RE:Update tomorrow better be good eh .
Agree. MDNA 11 update next up.
(120)
•••
ENEMENEMYNEMO
X
View Profile
View Bullboard History
Comment by
ENEMENEMYNEMO
on Apr 09, 2024 1:42pm
RE:RE:Update tomorrow better be good eh .
More to come....
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 09, 2024 12:02pm
New Press Release - Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
MDNA113 is targeted to the tumor site where it is activated to simultaneously deliver two immunotherapies, an IL-2 superkine and anti-PD1 antibody, to the same cancer fighting immune cells in the tumor micro-environment (TME) to maximize efficacy and minimize systemic toxicityMDNA113 is our most...
read article.
(580)
•••
Galaxym31
X
View Profile
View Bullboard History
Comment by
Galaxym31
on Apr 08, 2024 7:13pm
RE:Update tomorrow better be good eh .
Forgot to mention Medicenna .
(580)
•••
Galaxym31
X
View Profile
View Bullboard History
Post by
Galaxym31
on Apr 08, 2024 6:54pm
Update tomorrow better be good eh .
Moose Jaw Sask .
(580)
•••
Galaxym31
X
View Profile
View Bullboard History
Comment by
Galaxym31
on Apr 08, 2024 10:07am
RE:RE:RE:Abstract
why not two treatments ?
(120)
•••
ENEMENEMYNEMO
X
View Profile
View Bullboard History
Comment by
ENEMENEMYNEMO
on Apr 07, 2024 5:05pm
RE:RE:Abstract
These are dying patients. No further options. Give a guy an extra 6 months to see his grandkid graduate university, or his child born, or make it to his 50th wedding anniversary. What's that worth
...more
(580)
•••
Galaxym31
X
View Profile
View Bullboard History
Comment by
Galaxym31
on Apr 07, 2024 2:30pm
RE:Abstract
One PR out of 16 is not a WOW to me .
(120)
•••
ENEMENEMYNEMO
X
View Profile
View Bullboard History
Post by
ENEMENEMYNEMO
on Apr 06, 2024 3:52pm
Abstract
Pickin apart the data...remembering it's from November 23 (submission date) Clinical Benefit rate of 25% in Melanoma Group at 6 months. Wow! Total 16/1PR/3SD >6months
(99)
•••
windymayor1
X
View Profile
View Bullboard History
Comment by
windymayor1
on Apr 04, 2024 11:59am
RE:RE:RE:Pre Market
Was a Mkt sell order for 50k . Countered with mkt buy order and filled at $1.85.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
One Property, One Focus on Advancing this Gold Project in Ontario
Options Trading for Retiring: Key Strategies in Balancing Retirement Income